ZYME PEER ANALYSIS

Zymeworks Inc. Common Stock — metric-by-metric comparison with peers and the industry median

ZYMEZymeworks Inc. Common Stock

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile

ZYMEIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year

Split-adjusted

Year-to-Date (YTD)

Key Metric Comparison

P/E

Lower is better

ROE

Higher is better

Net Margin

Higher is better

Revenue Growth

Higher is better

All Metrics

Valuation
Metric	ZYME	TLX	MSB	CSL	Ind. Median
P/E	—	—	—	29.96	18.06
P/B	12.20	6.38	—	2.24●	3.62
EV/EBITDA	—	120.20	—	10.35●	15.13
P/S	24.56	3.24	31.30	2.66●	10.65

Financial Health
Metric	ZYME	TLX	MSB	CSL	Ind. Median
Current Ratio	10.82●	1.43	—	2.57	5.90
Debt/Equity	10.4%●	112.3%	—	67.4%	10.9%
NetDebt/EBITDA	3.69	13.13	—	2.22●	1.15

Profitability
Metric	ZYME	TLX	MSB	CSL	Ind. Median
Net Margin	-126.3%	-0.9%	-115.3%	9.2%●	-125.7%
ROE	-42.0%	-1.8%	-11.3%	7.7%●	-47.5%
ROA	-22.7%	-0.7%	-8.6%	3.8%●	-35.8%
EBITDA Margin	-116.1%	3.0%	-76.6%	32.8%●	-105.8%

Growth + Dividend
Metric	ZYME	TLX	MSB	CSL	Ind. Median
Rev. Growth	-13.0%	56.3%	410.4%●	4.8%	5.1%
NI Growth	—	—	—	-39.4%	12.1%
Div. Yield	—	—	0.0%	2.5%●	0.2%
Payout	—	—	0.0%	103.1%	0.0%

Valuation
Metric	ZYME	VRDN	RXRX	URGN	INVA	TYRA	Ind. Median
P/E	—	—	—	—	3.74	—	18.06
P/B	12.20	3.29	1.98	-15.25●	1.41	5.09	3.62
EV/EBITDA	—	—	—	—	2.51	—	15.13
P/S	24.56	29.50	30.66	13.48	4.45●	—	10.65

Financial Health
Metric	ZYME	VRDN	RXRX	URGN	INVA	TYRA	Ind. Median
Current Ratio	10.82	15.15	5.47	4.69	21.13●	20.49	5.90
Debt/Equity	10.4%	8.0%	7.1%	-158.6%●	24.7%	1.5%	10.9%
NetDebt/EBITDA	3.69	2.03	1.21	-0.48●	-0.44	2.89	1.15

Profitability
Metric	ZYME	VRDN	RXRX	URGN	INVA	TYRA	Ind. Median
Net Margin	-126.3%	-508.5%	-844.5%	-94.8%	118.9%●	—	-125.7%
ROE	-42.0%	-58.1%	-57.2%	—	50.7%●	-36.9%	-47.5%
ROA	-22.7%	-49.7%	-42.3%	-53.2%	32.6%●	-34.7%	-35.8%
EBITDA Margin	-116.1%	-492.7%	-723.3%	-82.4%	150.9%●	—	-105.8%

Growth + Dividend
Metric	ZYME	VRDN	RXRX	URGN	INVA	TYRA	Ind. Median
Rev. Growth	-13.0%	23,382.8%●	11.0%	52.9%	13.6%	-100.0%	5.1%
NI Growth	—	—	—	—	—	—	12.1%
Div. Yield	—	—	—	—	—	—	0.2%
Payout	—	—	—	—	—	—	0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on ZYME

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 7, 26. This content is for informational purposes only and is not investment advice.